Immunoconjugates

• 

  Subject Areas on Research

  • A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. 
  • A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis. The Xoma RA Investigator Group. 
  • A new look at blockade of T-cell costimulation: a therapeutic strategy for long-term maintenance immunosuppression. 
  • A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia. 
  • A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254. 
  • A polar substituent-containing acylation agent for the radioiodination of internalizing monoclonal antibodies: N-succinimidyl 4-guanidinomethyl-3-[131I]iodobenzoate ([131I]SGMIB). 
  • A single peptide-major histocompatibility complex ligand triggers digital cytokine secretion in CD4(+) T cells. 
  • Abundant tyrosine residues in the antigen binding site in anti-osteosarcoma monoclonal antibodies TP-1 and TP-3: Application to radiolabeling. 
  • Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates. 
  • Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts. 
  • Antibody-targeted photodynamic therapy. 
  • Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. 
  • Autocrine growth factors and neuroendocrine markers in the development of small-cell lung cancer. 
  • Belatacept and sirolimus prolong nonhuman primate islet allograft survival: adverse consequences of concomitant alefacept therapy. 
  • Belatacept and sirolimus prolong nonhuman primate renal allograft survival without a requirement for memory T cell depletion. 
  • Belatacept: is there BENEFIT for liver transplantation too? 
  • Biokinetics of yttrium-90--labeled huBrE-3 monoclonal antibody. 
  • CD40 blockade combines with CTLA4Ig and sirolimus to produce mixed chimerism in an MHC-defined rhesus macaque transplant model. 
  • CTLA-4-Mediated inhibition of early events of T cell proliferation. 
  • CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. 
  • CTLA4Ig prevents alloantibody formation following nonhuman primate islet transplantation using the CD40-specific antibody 3A8. 
  • CTLA4Ig: bridging the basic immunology with clinical application. 
  • Costimulation blockade alters germinal center responses and prevents antibody-mediated rejection. 
  • Costimulator dependence of lymphokine secretion by naive and activated CD4+ T lymphocytes from TCR transgenic mice. 
  • Costimulatory molecules are active in the human xenoreactive T-cell response but not in natural killer-mediated cytotoxicity. 
  • Cutting edge: membrane lymphotoxin regulates CD8(+) T cell-mediated intestinal allograft rejection. 
  • Cytotoxic T lymphocyte antigen 4 (CTLA4) blockade accelerates the acute rejection of cardiac allografts in CD28-deficient mice: CTLA4 can function independently of CD28. 
  • High CTLA-4 expression on Th17 cells results in increased sensitivity to CTLA-4 coinhibition and resistance to belatacept. 
  • High-level production of alpha-particle-emitting (211)At and preparation of (211)At-labeled antibodies for clinical use. 
  • IFN-gamma dictates allograft fate via opposing effects on the graft and on recipient CD8 T cell responses. 
  • Identification of potential cytokine pathways for therapeutic intervention in murine primary biliary cirrhosis. 
  • Immune status assay (ISA): a noninvasive procedure for studying allograft rejection. 
  • In vitro cytotoxicity of 211At-labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fraction. 
  • In vivo T cell costimulation blockade with abatacept for acute graft-versus-host disease prevention: a first-in-disease trial. 
  • Inducing unresponsiveness by the use of anti-CD3 immunotoxin, CTLA4-Ig, and anti-CD40 ligand. 
  • Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. 
  • LFA-1 blockade induces effector and regulatory T-cell enrichment in lymph nodes and synergizes with CTLA-4Ig to inhibit effector function. 
  • Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding. 
  • Molecular basis of T cell inactivation by CTLA-4. 
  • Monoclonal antibodies for brain tumour treatment. 
  • Monoclonal antibody therapy for malignant glioma. 
  • Monoclonal antibody therapy in the treatment of non-Hodgkin lymphoma. 
  • Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer. 
  • Preclinical Evaluation of 18F-Labeled Anti-HER2 Nanobody Conjugates for Imaging HER2 Receptor Expression by Immuno-PET. 
  • Preclinical toxicity evaluation of a novel immunotoxin, D2C7-(scdsFv)-PE38KDEL, administered via intracerebral convection-enhanced delivery in rats. 
  • Preparation and characterization of anti-tenascin monoclonal antibody-streptavidin conjugates for pretargeting applications. 
  • Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study. 
  • Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates. 
  • Radioiodinated antibody targeting of the HER-2/neu oncoprotein: effects of labeling method on cellular processing and tissue distribution. 
  • Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody. 
  • Renal transplantation using belatacept without maintenance steroids or calcineurin inhibitors. 
  • Role of interleukin 12 and costimulators in T cell anergy in vivo. 
  • Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. 
  • Selective costimulation modulation with abatacept: a look at quality-of-life outcomes in patients with rheumatoid arthritis. 
  • Selective targeting of human alloresponsive CD8+ effector memory T cells based on CD2 expression. 
  • The allo- and viral-specific immunosuppressive effect of belatacept, but not tacrolimus, attenuates with progressive T cell maturation. 
  • Therapeutic effect of cytotoxic T lymphocyte antigen 4/immunoglobulin on a murine model of primary biliary cirrhosis. 
  • Three-dimensional molecular imaging with photothermal optical coherence tomography. 
  • Two approaches for enhancing radioimmunotherapy: alpha emitters and hyperthermia.